Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SXTP
SXTP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SXTP News
U.S. Stocks Rise in Morning Trading, Dow Up Over 100 Points
Jan 26 2026
Benzinga
Baker Hughes Q4 Earnings Exceed Expectations
Jan 26 2026
Benzinga
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
Jan 22 2026
Benzinga
60 Degrees Pharmaceuticals (SXTP) Partners with Runway Health to Launch Arakoda, Stock Surges 161%
Jan 22 2026
stocktwits
Procter & Gamble (PG) Stock Rises 2% After Beating EPS Estimates in Mixed Q2 Results
Jan 22 2026
Benzinga
60 Degree Pharmaceuticals (SXTP) Announces 1-for-4 Reverse Stock Split to Regain Nasdaq Compliance
Jan 16 2026
NASDAQ.COM
60 Degrees Pharmaceuticals (SXTP) to Implement 1-for-4 Reverse Stock Split Effective January 20, 2026
Jan 15 2026
seekingalpha
60 Degrees Pharma Confirms B-FREE Study for ARAKODA® in Chronic Babesiosis Treatment
Dec 29 2025
Globenewswire
60 Degrees Pharma Confirms B-FREE Study for ARAKODA in Chronic Babesiosis Treatment
Dec 29 2025
Newsfilter
60 Degrees Pharma Expands Sales Team to Boost ARAKODA Sales
Dec 11 2025
Globenewswire
60 Degrees Pharma Expands Sales Team to Boost ARAKODA Sales
Dec 11 2025
Newsfilter
Dick's Sporting Goods Set to Surge by 17%? Check Out 10 Leading Analyst Predictions for Friday
Nov 28 2025
Benzinga
Ascendiant Capital Reaffirms Buy Rating on 60 Degrees, Adjusts Price Target to $2.8
Nov 28 2025
Benzinga
60 Degrees Launches Central Location for Patient Enrollment in B-FREE Study
Nov 22 2025
Yahoo Finance
HC Wainwright & Co. Initiates Coverage on 60 Degrees with a Buy Rating and Sets Price Target at $6
Nov 14 2025
Benzinga
60 Degrees Pharmaceuticals Reveals Name of Clinical Trial for Chronic Babesiosis: B-FREE Study
Oct 09 2025
Newsfilter
Show More News
